Yukiko Shimoda

Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC

Masayuki Shirasawa, Tatsuya Yoshida, Yukiko Shimoda et al. · Journal of Thoracic Oncology · 2021 · 61 citations · Full text

Inflammation, Advanced Nsclc, Cancer Immunosurveillance +12

Substance P-evoked Cl⁻secretion in guinea pig distal colonic epithelia: interaction with PGE₂

Yutaka Hosoda, Shin-ichiro Karaki, Yukiko Shimoda et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 2002 · 24 citations

Gastrointestinal Pharmacology, Gastroenterology, Digestive Tract +19

Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients

Yukiko Shimoda, Ryota Shibaki, Tatsuya Yoshida et al. · Clinical Lung Cancer · 2022 · 18 citations

Cancer Immunosurveillance, Autoimmune Disease, Novel Therapy +7

Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis

Masahiro Torasawa, Tatsuya Yoshida, Shigehiro Yagishita et al. · Lung Cancer · 2022 · 13 citations

Medicine, Propensity-matched Real-world Analysis, Immune Checkpoint Inhibitor +6

Improved cough- and sputum-related quality of life after initiation of treatment in pulmonary tuberculosis

Takahito Suzuki, Toshihiro Shirai, Keita Hirai et al. · Respiratory Investigation · 2019 · 12 citations

Pulmonary Tuberculosis, Tuberculosis Prevention, Tuberculosis +3